Biocon clears patent hurdle for breast cancer biosimilar Pebrilzo
Statements (3)
- Bullish
Biocon secures U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay) Injection, a biosimilar to Perjeta®.
- Bullish
Biocon shares gain after US FDA approves cancer drug biosimilar
- Bullish
Biocon received USFDA approval for Pebrilzo, its fifth cancer biosimilar